ARCA biopharma, Inc.

ARCA biopharma, Inc.verified

ABIO

Price:

$28.8

Market Cap:

$34.82M

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorad...[Read more]

Industry

Biotechnology

IPO Date

1997-08-08

Stock Exchange

NASDAQ

Ticker

ABIO

The ROE as of December 2024 (TTM) for ARCA biopharma, Inc. (ABIO) is -20.18%

According to ARCA biopharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -20.18%. This represents a change of 291.29% compared to the average of -5.16% of the last 4 quarters.

ARCA biopharma, Inc. (ABIO) Historical ROE (quarterly & annually)

How has ABIO ROE performed in the past?

The mean historical ROE of ARCA biopharma, Inc. over the last ten years is -64.87%. The current -20.18% ROE has changed -68.88% with respect to the historical average. Over the past ten years (40 quarters), ABIO's ROE was at its highest in in the December 2022 quarter at -1.92%. The ROE was at its lowest in in the December 2017 quarter at -40.84%.

Quarterly (TTM)
Annual

Average

-64.87%

Median

-51.70%

Minimum

-179.95%

Maximum

-14.42%

ARCA biopharma, Inc. (ABIO) ROE by Quarter and Year

Discovering the peaks and valleys of ARCA biopharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 146.74%

Maximum Annual ROE = -14.42%

Minimum Annual Increase = -70.94%

Minimum Annual ROE = -179.95%

Quarterly (TTM)
Annual
YearROEChange
2023-14.42%-35.07%
2022-22.21%-41.05%
2021-37.68%79.99%
2020-20.93%-70.94%
2019-72.04%-45.21%
2018-131.48%-26.93%
2017-179.95%142.59%
2016-74.18%146.74%
2015-30.06%-54.26%
2014-65.73%47.59%

ARCA biopharma, Inc. (ABIO) Average ROE

How has ABIO ROE performed in the past?

The current ROE of ARCA biopharma, Inc. (ABIO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-24.77%

5-year avg

-33.46%

10-year avg

-64.87%

ARCA biopharma, Inc. (ABIO) ROE vs. Peers

How is ABIO’s ROE compared to its peers?

ARCA biopharma, Inc.’s ROE is greater than Aerovate Therapeutics, Inc. (-90.19%), greater than Adagene Inc. (-50.10%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.95%), greater than Rezolute, Inc. (-69.83%), greater than AN2 Therapeutics, Inc. (-57.63%), greater than Indaptus Therapeutics, Inc. (-177.27%), greater than Tempest Therapeutics, Inc. (-187.44%), less than Comera Life Sciences Holdings, Inc. (67.46%), greater than Forte Biosciences, Inc. (-151.43%), less than ZIVO Bioscience, Inc. (618.61%), greater than RenovoRx, Inc. (-242.57%), greater than Pasithea Therapeutics Corp. (-81.66%), greater than Quoin Pharmaceuticals, Ltd. (-126.19%), greater than Sio Gene Therapies Inc. (-78.26%), greater than Magenta Therapeutics, Inc. (-14.27%), less than TRACON Pharmaceuticals, Inc. (0%), greater than CytomX Therapeutics, Inc. (-237.65%), greater than Spero Therapeutics, Inc. (-41.34%), less than Neoleukin Therapeutics, Inc. (3.36%), greater than Instil Bio, Inc. (-8.54%), greater than NextCure, Inc. (-37.44%), greater than null (-62.50%),

Build a custom stock screener for ARCA biopharma, Inc. (ABIO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ARCA biopharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ARCA biopharma, Inc. (ABIO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ARCA biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is ARCA biopharma, Inc.'s ROE?

How is the ROE calculated for ARCA biopharma, Inc. (ABIO)?

What is the highest ROE for ARCA biopharma, Inc. (ABIO)?

What is the 3-year average ROE for ARCA biopharma, Inc. (ABIO)?

What is the 5-year average ROE for ARCA biopharma, Inc. (ABIO)?

How does the current ROE for ARCA biopharma, Inc. (ABIO) compare to its historical average?